Table of Contents
What Are Overactive Bladder Medications?
Overactive bladder medications are prescription drugs that change the chemical signaling involved in bladder storage and contractions.
They are primarily used for overactive bladder (OAB) and urgency urinary incontinence, where someone experiences sudden, difficult-to-control urges to urinate and may leak before reaching the bathroom.
Medication can help reduce:
- Sudden urinary urgency
- Frequent bathroom trips
- Urgency-related urine leakage
- Some nighttime urinary symptoms associated with OAB
They do not all work equally well for every person, and the choice of drug often comes down to balancing symptom improvement against side effects, medical history, cost, and personal preference.
Which Type of Incontinence Do Medications Treat?
This distinction is important because the medications discussed here are primarily treatments for OAB and urge incontinence.
If you leak when you cough, sneeze, laugh, jump, exercise, or lift something, that is more characteristic of stress urinary incontinence. OAB medications do not strengthen the pelvic floor or correct inadequate urethral support.
If you have sudden urgency and sometimes leak before reaching the bathroom, medication may be one treatment option.
If you experience both types of leakage, you may have mixed urinary incontinence and may need to address both mechanisms.
The 2 Main Types of OAB Medication
Most oral OAB medications fall into two major classes:
- Antimuscarinics block acetylcholine signaling that contributes to bladder contractions.
- Beta-3 agonists activate beta-3 adrenergic receptors to help the bladder muscle relax during filling.
Both can improve OAB symptoms, but their side-effect profiles differ substantially.
Antimuscarinic Medications
Antimuscarinics have been used to treat OAB for decades.
Common examples include:
- Oxybutynin (Ditropan)
- Tolterodine (Detrol)
- Solifenacin (Vesicare)
- Darifenacin (Enablex)
- Fesoterodine (Toviaz)
- Trospium
These drugs block muscarinic receptors activated by the neurotransmitter acetylcholine. Acetylcholine normally plays an important role in triggering contractions of the detrusor, the muscle in the bladder wall.
Reducing that signaling can help the bladder remain relaxed during filling and decrease urgency, frequency, and urge-related leakage.
Antimuscarinic Side Effects and Cognitive Concerns
The same neurotransmitter system involved in bladder contractions also functions elsewhere in the body. As a result, antimuscarinic medications can produce effects outside the bladder.
Common side effects include:
- Dry mouth
- Constipation
- Blurred vision
- Dry eyes
- Drowsiness or dizziness with some medications
- Difficulty emptying the bladder or urinary retention
Dry mouth and constipation are among the most common reasons these medications can be difficult to tolerate long term.
What About Dementia and Cognitive Risk?
Long-term anticholinergic exposure has also raised concern about cognitive effects.
The 2024 American Urological Association/SUFU guideline specifically recommends that clinicians discuss the potential risk of dementia and cognitive impairment with patients who take or are considering antimuscarinic medications for OAB.
This does not mean that everyone who takes an antimuscarinic will develop dementia. Research has found an association between cumulative anticholinergic exposure and dementia risk, but individual risk varies by medication, duration, dose, age, and other health factors.
The issue is particularly important for older adults and people already at increased risk for cognitive impairment.
Beta-3 Agonists: Mirabegron and Vibegron
Beta-3 adrenergic agonists are a newer class of OAB medication.
The two medications currently used in the United States are:
- Mirabegron (Myrbetriq)
- Vibegron (Gemtesa)
Instead of blocking acetylcholine, these medications stimulate beta-3 adrenergic receptors in the detrusor muscle.
This helps the bladder relax during the filling phase so it can store urine with less urgency and fewer unwanted contractions.
Because beta-3 agonists do not have the same anticholinergic mechanism, they generally cause less dry mouth and constipation and do not carry the same anticholinergic cognitive concerns.
Beta-3 Agonist Side Effects and Limitations
Beta-3 agonists are often better tolerated than antimuscarinics, but they are not side-effect free.
Potential considerations include:
- Headache
- Urinary tract infection
- Nasopharyngitis or cold-like symptoms
- Possible difficulty emptying the bladder in susceptible patients
- Drug interactions depending on the medication
Cardiovascular effects are also considered when choosing a beta-3 agonist.
Mirabegron carries a warning regarding blood pressure and is not recommended for people with severe uncontrolled hypertension. Vibegron does not carry that same severe-hypertension warning. Current AUA guidance specifically notes this difference between the two drugs.
Cost and insurance coverage can also influence which medication is practical. Rather than assigning a fixed monthly price, it is better to check your individual prescription coverage because out-of-pocket costs vary widely among plans.
Medication Comparison
